Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

MS, Gordon; M, Hussey; RB, Nagle; PN Jr, Lara; PC, Mack; J, Dutcher; W, Samlowski; JI, Clark; DI, Quinn; CX, Pan; D, Crawford

doi:10.1200/jco.2008.18.8821

Public

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Shared by NobleBlocks on Nov 2, 2009 • 12:00 AM UTC

Authors:

Gordon MS

Hussey M

Nagle RB

Abstract

<h4>Purpose</h4>Patients with advanced papillary renal cell cancer (pRCC) have poor survival after systemic therapy; the reported median survival time is 7 to 17 months. In this trial, we evaluated the efficacy of erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor i...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!